Bionano Genomics (BNGO) Total Liabilities (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Total Liabilities data on file, last reported at $27.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 9.54% year-over-year to $27.3 million; the trailing twelve-month figure through Mar 2026 stood at $27.3 million (down 9.54% YoY), and the FY2025 full-year result was $29.2 million, down 29.39% from the prior year.
• Total Liabilities slipped to $27.3 million in Q1 2026, from $29.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $118.2 million in Q4 2023 to a low of $27.3 million in Q1 2026.
• A 5-year average of $48.4 million and a median of $41.3 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 236.45% in 2022 and slumped 65.08% in 2024, its largest moves.
• Tracing BNGO's Total Liabilities over 5 years: stood at $58.1 million in 2022, then surged by 103.51% to $118.2 million in 2023, then tumbled by 65.08% to $41.3 million in 2024, then fell by 29.39% to $29.2 million in 2025, then dropped by 6.24% to $27.3 million in 2026.
• Business Quant data shows BNGO's Total Liabilities at $27.3 million in Q1 2026, $29.2 million in Q4 2025, and $29.3 million in Q3 2025.